Implementing a national programme of pathogen genomics for public health: the Australian Pathogen Genomics Program (AusPathoGen)

作者：Jessica R. Webb, Patiyan Andersson, Eby M. Sim, Alireza Zahedi, Angela Donald, Tuyet Hoang, Anne E. Watt, Jessica E. Agius, Celeste M. Donato, Max Laurence Cummins, Tehzeeb Zulfiqar, Son Hong Nghiem, Chantel Lin, Dimitrios Menouhos, Lex E. X. Leong, Robert Baird, Karina Kennedy, Louise Cooley, David John Speers, Chuan Kok Lim, Joep de Ligt, Angeline Samantha Ferdinand, Katie Glass, Martyn Kirk, Steven Philip Djordjevic, Clare Sloggett, Kristy Horan, Torsten Seemann, Vitali Sintchenko, Amy V. Jennison, Benjamin P. Howden · 发表于：The Lancet Microbe · 年份：2024 · DOI：10.1016/j.lanmic.2024.100969 · 被引用次数：16 · 研究领域：Zoonotic diseases and public health、Viral gastroenteritis research and epidemiology、Animal Disease Management and Epidemiology

Delivering large-scale routine pathogen genomics surveillance for public health is of considerable interest, although translational research models that promote national-level implementation are not well defined. We describe the development and deployment of the Australian Pathogen Genomics Program (AusPathoGen), a comprehensive national partnership between academia, public health laboratories, and public health agencies that commenced in January, 2021. Successfully establishing and delivering a national programme requires inclusive and transparent collaboration between stakeholders, defined and clear focus on public health priorities, and support for strengthening national genomics capacity. Major enablers for delivering such a programme include technical solutions for data integration and analysis, such as the genomics surveillance platform AusTrakka, standard bioinformatic analysis methods, and national ethics and data sharing agreements that promote nationally integrated surveillance systems. Training of public health officials to interpret and act on genomic data is crucial, and evaluation and cost-effectiveness programmes will provide a benchmark and evidence for sustainable investment in genomics nationally and globally.